Bind Goes Public for Accurin Development
By Catherine Shaffer
Tuesday, August 13, 2013
Bind Therapeutics Inc. plans to give the public a chance to invest in its pipeline of programmable therapeutics in an initial public offering worth $80.5 million. The cash influx will support development of its Accurins, compounds designed to target specific cells or tissues and deliver a payload to the site of disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.